Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 4
1986 3
1997 2
1998 2
1999 2
2000 2
2002 2
2003 1
2004 1
2010 3
2011 3
2012 6
2013 3
2014 7
2015 14
2016 6
2017 7
2018 2
2019 7
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Pollack CV Jr, et al. Among authors: van ryn j. N Engl J Med. 2017 Aug 3;377(5):431-441. doi: 10.1056/NEJMoa1707278. Epub 2017 Jul 11. N Engl J Med. 2017. PMID: 28693366 Free article. Clinical Trial.
Idarucizumab: The Antidote for Reversal of Dabigatran.
Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Eikelboom JW, et al. Among authors: van ryn j. Circulation. 2015 Dec 22;132(25):2412-22. doi: 10.1161/CIRCULATIONAHA.115.019628. Circulation. 2015. PMID: 26700008 Review. No abstract available.
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Eisert WG, et al. Among authors: van ryn j. Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1885-9. doi: 10.1161/ATVBAHA.110.203604. Epub 2010 Jul 29. Arterioscler Thromb Vasc Biol. 2010. PMID: 20671233 Review.
COX-2 selectivity and inflammatory processes.
van Ryn J, Trummlitz G, Pairet M. van Ryn J, et al. Curr Med Chem. 2000 Nov;7(11):1145-61. doi: 10.2174/0929867003374255. Curr Med Chem. 2000. PMID: 11032964 Review.
The discovery of dabigatran etexilate.
van Ryn J, Goss A, Hauel N, Wienen W, Priepke H, Nar H, Clemens A. van Ryn J, et al. Front Pharmacol. 2013 Feb 12;4:12. doi: 10.3389/fphar.2013.00012. eCollection 2013. Front Pharmacol. 2013. PMID: 23408233 Free PMC article.
Impact of Rabeprazole on APO-Dabigatran Exposure in Healthy Volunteers.
Chan N, Wheeler M, Bhagirath V, Bosch J, Heinrich-Nols J, Sloane D, van Ryn J, Jefferies L, Wilkinson J, Yi Q, Eikelboom J. Chan N, et al. Among authors: van ryn j. CJC Open. 2022 Oct 12;5(1):1-7. doi: 10.1016/j.cjco.2022.09.006. eCollection 2023 Jan. CJC Open. 2022. PMID: 36700178 Free PMC article.
Thrombin promotes diet-induced obesity through fibrin-driven inflammation.
Kopec AK, Abrahams SR, Thornton S, Palumbo JS, Mullins ES, Divanovic S, Weiler H, Owens AP 3rd, Mackman N, Goss A, van Ryn J, Luyendyk JP, Flick MJ. Kopec AK, et al. Among authors: van ryn j. J Clin Invest. 2017 Aug 1;127(8):3152-3166. doi: 10.1172/JCI92744. Epub 2017 Jul 24. J Clin Invest. 2017. PMID: 28737512 Free PMC article.
80 results